Patents Examined by Jeffrey E. Russel
  • Patent number: 10835578
    Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: November 17, 2020
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
  • Patent number: 10821151
    Abstract: The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: November 3, 2020
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober
  • Patent number: 10821094
    Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of a squamous epithelium in a target tissue using alpha-1 proteinase inhibitors to replenish SPINK7 protein and/or SPINK7 anti-proteinase activity in the target tissue, and related methods and compositions.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 3, 2020
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Nurit P. Azouz, Marc E. Rothenberg
  • Patent number: 10815287
    Abstract: Provided is an acylated derivative of human insulin or an analogue thereof. Specifically disclosed is an acylated derivative of a human insulin analogue, or zinc complex thereof; the human insulin analogue being derivatized is preferably Des(B30) human insulin; the acylated derivative is longer-lasting than existing insulin analogues and acylated derivatives thereof, its blood glucose reduction is more steady, and it is more stable in storage.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 27, 2020
    Assignee: JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Deyu Liu, Hongwei Wang, Liang Zhao, Feifei Wang, Xiang Zeng, Tao Wang, Yali Wang, Yulu Dai
  • Patent number: 10799564
    Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: October 13, 2020
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Joseph Chung Tak Wong, Sarah Elizabeth Lee
  • Patent number: 10800817
    Abstract: A method for treating a cancer comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising an anti-cancer agent having at least one secretion modifying region (SMR) peptide from HIV-1 Nef fused to at least one cell-penetrating peptide (CPP) or at least one Clusterin (Clu)-binding peptide (Clu-BP).
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 13, 2020
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent C. Bond, James W. Lillard, Jr., Ming Bo Huang
  • Patent number: 10792367
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart, Andreas Evers, Peyman Sakhaii, Pradeep K. Dhal, Paul Konowicz, James E. Stefano, Nils Poth
  • Patent number: 10793307
    Abstract: The enclosed disclosure describes, among other things, a method including the steps of a first deaerating step in which a mixture comprising peptides is deaerated by lowering the pressure, filtering the mixture through a sterilizing filter; and a second deaerating step, in which the filtrate is deaerated by vibration and lowering the pressure.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: October 6, 2020
    Assignee: 3-D Matrix, Ltd.
    Inventors: Masahiro Nohara, Yuya Hasegawa
  • Patent number: 10787485
    Abstract: The invention relates to a peptide comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin binding peptide, and (iii) at least one heparin binding peptide. The invention further relates to a coating for metal surfaces comprising the peptide according to the invention and a coated metal surface which promotes osseointegration that can be obtained by reacting the peptide according to the invention with a metal surface.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 29, 2020
    Assignee: Universität
    Inventors: Annette Beck-Sickinger, Mareen Pagel, Rayk Hassert
  • Patent number: 10786542
    Abstract: Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (V): wherein R1 and R2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: September 29, 2020
    Inventors: Jeffrey D. Laskin, Ron Udasin, Lauren Aleksunes
  • Patent number: 10786543
    Abstract: The present invention provides 75 kD transmembrane neurotrophin receptor (p75NTR) antagonists and their use in prevention and treatment of loss of function, and adverse remodeling, in cardiac tissues subject to acute or chronic hemodynamic stress. Uses of the antagonists with or without additional cardiotropic agents for improving contractility and for treatment of congestive heart failure are also provided.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 29, 2020
    Assignees: The Johns Hopkins University, Vanderbilt University
    Inventors: Nazareno Paolocci, Ning Feng, Carlo G. Tocchetti, Cyrus Takahashi, Bruce Carter
  • Patent number: 10787492
    Abstract: An improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. The iCP-SOCS3 recombinant protein may be used as protein-based anti-angiogenic agent by utilizing the platform technology for macromolecule intracellular transduction. The iCP-SOCS3 recombinant protein includes a SOCS3 protein and at least one advanced macromolecule transduction domain (aMTD)(s). The aMTD(s) is composed of 9-13 amino acid residues and has the following features (a)-(c): (a) having 3 or more amino acid residues independently selected from the group consisting of Ala, Val, Ile, Leu, and Pro; (b) having Proline as an amino acid residue corresponding to any one or more of positions 5, 7 and 8, and position 12 of its amino acid sequence; and (c) having an instability index of 40-60, an aliphatic index of 180-220, and a grand average of hydropathy (GRAVY) score of 2.1-2.6, according to Protparam computational formula.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 29, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Patent number: 10772861
    Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 15, 2020
    Assignees: Leading Biosciences, LLC, The Regents of the University of California
    Inventors: Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
  • Patent number: 10774113
    Abstract: The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 15, 2020
    Assignee: Eberhard Karls Universitaet Tuebingen
    Inventors: Bernhard Krismer, Andreas Peschel, Stephanie Grond, Alexander Zipperer, Martin Christoph Konnerth, Daniela Janek, Hubert Kalbacher, Nadine Anna Schilling
  • Patent number: 10765754
    Abstract: Disclosed herein are compositions and methods for inhibiting respiratory syncytial virus (RSV) entry into a host cell. Also provided herein are methods of identifying a peptide that interacts with the N-trimer of RSV F protein.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: September 8, 2020
    Assignees: Navigen, Inc., University of Utah Research Foundation
    Inventors: Brett D. Welch, Michael S. Kay, Debra Muir Eckert, Rena McKinnon, Michael Thomas Jacobsen
  • Patent number: 10765721
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 8, 2020
    Assignee: Ferring B.V
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Patent number: 10758589
    Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: September 1, 2020
    Assignee: NoNO Inc.
    Inventor: Jonathan David Garman
  • Patent number: 10745442
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 18, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Patent number: 10745454
    Abstract: The embodiments herein disclose a method for synthesizing antagonistic peptide VEGF and bFGF. The method comprises synthesizing the antagonistic peptide for VEGF and bFGF and analyzing the purity of peptides. The quality of antagonistic peptide for VEGF and bFGF is analyzed by HPLC chromatogram and Mass spectrometry analysis. The biochemical activity of the antagonistic peptide for VEGF and bFGF is analyzed by competitive binding assay, cell proliferation assay, Matrigel assay for anti-angiogenic activity analysis, histopathological staining and Western blot analysis. The competitive binding assay of antagonistic peptide for VEGF and bFGF illustrate that peptides binds with cell receptors at a concentration of 2000 ng/ml. The cell proliferation assay illustrates that cell growth is arrested when antagonistic peptide for VEGF and bFGF are at a concentration of 2000 ng/ml.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 18, 2020
    Inventors: Seyed Mohsen Asghari, Somayeh Ehtesham
  • Patent number: 10745441
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: August 18, 2020
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang